fruquintinib + sintilimab + paclitaxel + doxorubicin
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Endometrial Cancer
Conditions
Advanced Endometrial Cancer
Trial Timeline
Dec 12, 2024 → Jun 9, 2029
NCT ID
NCT06584032About fruquintinib + sintilimab + paclitaxel + doxorubicin
fruquintinib + sintilimab + paclitaxel + doxorubicin is a phase 3 stage product being developed by HUTCHMED for Advanced Endometrial Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06584032. Target conditions include Advanced Endometrial Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06584032 | Phase 3 | Recruiting |
Competing Products
20 competing products in Advanced Endometrial Cancer